[PDF][PDF] Role of dietary fiber in the recovery of the human gut microbiome and its metabolome
…, L Nessel, UR Paladhi, L Chau, E Panfen… - Cell host & …, 2021 - cell.com
Gut microbiota metabolites may be important for host health, yet few studies investigate the
correlation between human gut microbiome and production of fecal metabolites and their …
correlation between human gut microbiome and production of fecal metabolites and their …
Dissecting the contribution of OATP1B1 to hepatic uptake of statins using the OATP1B1 selective inhibitor estropipate
Y Zhang, E Panfen, M Fancher, M Sinz… - Molecular …, 2019 - ACS Publications
Identification of a selective inhibitor of organic anion transporting polypeptide (OATP) 1B1 is
critical in order to determine the contribution of OATP1B1-mediated uptake of investigational …
critical in order to determine the contribution of OATP1B1-mediated uptake of investigational …
Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein–Specific Endogenous Biomarker That …
…, DM Nelson, L Wang, R Huo, J Chen, E Panfen… - Drug Metabolism and …, 2023 - ASPET
Advancement of endogenous biomarkers for drug transporters as a tool for assessing drug-drug
interactions (DDIs) depends on initial identification of biomarker candidates and relies …
interactions (DDIs) depends on initial identification of biomarker candidates and relies …
Endogenous plasma kynurenic acid in human: a newly discovered biomarker for drug-drug interactions involving organic anion transporter 1 and 3 inhibition
…, TT Mariappan, Y Zhang, E Panfen… - Drug Metabolism and …, 2021 - ASPET
As an expansion investigation of drug-drug interaction (DDI) from previous clinical trials,
additional plasma endogenous metabolites were quantitated in the same subjects to further …
additional plasma endogenous metabolites were quantitated in the same subjects to further …
Enhanced and persistent inhibition of organic cation transporter 1 activity by preincubation of cyclosporine A
E Panfen, W Chen, Y Zhang, M Sinz, P Marathe… - Drug Metabolism and …, 2019 - ASPET
Recent pharmacogenetic evidence indicates that hepatic organic cation transporter (OCT) 1
can serve as the locus of drug-drug interactions (DDIs) with significant pharmacokinetic and …
can serve as the locus of drug-drug interactions (DDIs) with significant pharmacokinetic and …
Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions
J Chu, E Panfen, L Wang, A Marino, XQ Chen… - Pharmaceutical …, 2023 - Springer
Purpose The differences between intestinal and systemic (hepatic and renal) P-glycoprotein
(P-gp) and breast cancer resistance protein (BCRP) roles in drug disposition are difficult to …
(P-gp) and breast cancer resistance protein (BCRP) roles in drug disposition are difficult to …
[PDF][PDF] Endogenous plasma kynurenic acid in human: a newly discovered biomarker for drug-drug interactions involving in OAT1 and OAT3 inhibition
…, TT Mariappan, Y Zhang, E Panfen… - Drug Metabolism and …, 2021 - researchgate.net
249 Introduction: 930 Discussion: 1263 Reference: 33 Abbreviations: AUC, area under the
plasma concentration-time curve; Cmax, peak concentration; OAT, organic anion transporter; …
plasma concentration-time curve; Cmax, peak concentration; OAT, organic anion transporter; …
[HTML][HTML] Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects
SP Rendic - Archives of Toxicology, 2021 - Springer
The review presents metabolic properties of Ivermectin (IVM) as substrate and inhibitor of
human P450 (P450, CYP) enzymes and drug transporters. IVM is metabolized, both in vivo …
human P450 (P450, CYP) enzymes and drug transporters. IVM is metabolized, both in vivo …
Breast cancer resistance protein (BCRP) and sulfotransferases contribute significantly to the disposition of genistein in mouse intestine
W Zhu, H Xu, SWJ Wang, M Hu - The AAPS journal, 2010 - Springer
The low bioavailability of genistein has impeded its development into a therapeutic agent.
Our earlier studies indicate that glucuronidation is one of the major barriers to genistein oral …
Our earlier studies indicate that glucuronidation is one of the major barriers to genistein oral …
Intestinal efflux transporters P-gp and BCRP are not clinically relevant in apixaban disposition
Purpose The involvement of the intestinally expressed xenobiotic transporters P-glycoprotein
(P-gp) and Breast Cancer Resistance Protein (BCRP) have been implicated in apixaban …
(P-gp) and Breast Cancer Resistance Protein (BCRP) have been implicated in apixaban …